Industry

An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.

A large and rigorous meta-analysis fails to find support for the gene-environment interaction theory of depression.

New data fails to support the promotion of manualized psychotherapy as superior to non-manualized forms of psychotherapy.

A new as-yet-unpublished trial of duloxetine (Cymbalta) for fibromyalgia has presented more evidence of suicidal events in teens.

Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.

Between 2007 and 2016, the FDA identified 776 herbal supplements containing active, unapproved pharmaceutical chemicals.

New review ties increased screen time to increasing anxiety and depression among young adults throughout the United States.

A new study demonstrates how the choice of statistical techniques when examining data plays a large role in scientific outcomes.

A recent review suggests that depression guidelines do not incorporate evidence for exercise within a stepped-care approach and may be over-reliant on pharmacological treatments.

A recent Cochrane review has found that serious adverse events occur for about 1% of children and adolescents treated with Ritalin.

A new report on pediatric bipolar critically examines the current evidence base and calls for more research before the diagnosis is used.

Researchers examine the transformation of work, life, and identity in India as a result of Western corporate and psychological culture.

A new study, published in Psychological Medicine, found evidence for a specific type of publication bias distorting the evidence about antidepressant efficacy.

Can current guidelines for sleep, exercise, and screen time in childhood be linked to positive cognitive outcomes?

New research suggests that clinicians should exercise caution prescribing SNRIs as first-line treatment for mood and anxiety disorders.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.

Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.

A new study finds that sponsors of clinical trials in the EU continue to fail at reporting their results as required by recent legislation.

Reanalysis of the original primary outcome measure in the STAR*D study suggests STAR*D findings inflate improvement on antidepressant medication and exclusion criteria in conventional clinical trials results in overestimation of antidepressant efficacy.

New research demonstrates the benefits and complexities for immigrants transitioning from undocumented to DACA status.

An international study of college students reveals ubiquitous social and emotional challenges faced by young adults.

Two new articles find that rates of ADHD diagnosis and stimulant prescription continue to rise all over the world.

Without clarity and consensus around what social justice means, psychologists risk perpetuating injustices that undermine their stated mission.

Findings point to the role of withdrawal symptoms and prescriber practices in long-term antidepressant use.

Researchers offer a critical take on the inclusion of the Disruptive Mood Dysregulation Disorder in the DSM-V.